Heart with magnifying glass revealing a maze in a ventricle, alongside text reading 'ATTR-CM suspect & detect, uncover the clues for diagnosis'

Home > Educational resources

Educational resources

| Virtual Events

|  Sign up  to the ARiA 2020 E-meeting Series: Advances and Research in ATTR Amyloidosis
In the spirit of this rapidly evolving area, and in reflection of the current clinical and travel challenges, we are pleased to introduce a “live”, but virtually delivered,
ARiA 2020 E-meeting series. We will be joined by an international faculty of leading experts in the field of ATTR amyloidosis in the presentation and discussion of the following topics:

 

24 September                Suspicion and diagnosis of ATTR amyloidosis

22 October                     A new era for ATTR amyloidosis

5 November                   ATTR-CM Diagnosis in practice

3 December                   Looking to the future for patients with ATTR-CM

Sign up/ register here

| Expert videos

| Professor Perry Elliott (Bart's Heart Centre, London)

Professor Perry Elliott provides an overview of his symposium which concludes that looking for the underlying cause for heart failure classifications can lead to differential diagnosis of cardiomyopathy   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                     

This symposium at the BCS Annual Conference 2019 was an educational symposium organised and sponsored by Pfizer.
The content of the symposium was developed and agreed by the faculty.

 

| Dr Gerald Carr-White (Guy's and St Thomas' Hospital, London)

Investigating infiltrative cardiac disease as a subset of hypertrophic cardiomyopathy

Dr Gerald Carr-White summarises his symposium speech, discussing the red flags for identifying patients with infiltrative cardiac disease, which are now thought to make up around 10% of cases that may be misdiagnosed as left ventricular hypertrophy. He stresses the importance of identifying a systemic approach to treatment strategies, to ultimately improve patient outcomes.


This symposium at the BCS Annual Conference 2019 was an educational symposium organised and sponsored by Pfizer.
The content of the symposium was developed and agreed by the faculty.

 

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Mechanism of Disease

Learn how the amyloid is formed and deposited, resulting in ATTR-CM             

| Professor Perry Elliott (Bart's Heart Centre, London)

Investigating heart failure with preserved ejection fraction (HFpEF) and infiltrative cardiac disease

Professor Perry Elliott summarises his symposium speech, discussing the signs and symptoms of HFpEF and infiltrative cardiac diseases and the importance of finding the cause. He outlines how improving diagnostic criteria and treatment algorithms can help to decrease the co-morbidities and mortality associated with HFpEF, and how using a more personalised approach may help to better manage patients.


This symposium at the BCS Annual Conference 2019 was an educational symposium organised and sponsored by Pfizer.
The content of the symposium was developed and agreed by the faculty.         

                                                                                                                                                                                                                                                                                                                       

Dr Carol Jane Whelan (The NAC, Royal Free Hospital, London)

Investigating cardiac amyloidosis                                                                                                      

Dr Carol Jane Whelan summarises her symposium speech, explaining the difference between AL and ATTR cardiac amyloidosis, and discusses genetic mutations that cause hereditary ATTR-CM.  Dr Whelan encourages the use of nuclear scintigraphy as a diagnostic tool, reducing the need for an invasive biopsy.                                                                                                                                                                                                                        

This symposium at the BCS Annual Conference 2019 was an educational symposium organised and sponsored by Pfizer.
The content of the symposium was developed and agreed by the faculty.

| Downloadable Resources

| ATTR-CM Educational Slide Deck

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Uncovering the Clues for Diagnosis. Downloadable PowerPoint Presentation to support peer-to-peer education. This presentation contains an overview of cardiac amyloidosis, mechanism of disease for ATTR-CM, how to raise suspicion of ATTR-CM and how to diagnose the disease. Click below to download.

ATTR-CM peer to peer education deck Tafamidis (vyndaqel) peer to peer slide deck

 

| Vyndaqel ▼: Risk Management Material (RMM)

Important information about Vyndaqel (tafamidis): A guide for Healthcare Professionals. Click below to download.

Vyndaqel Risk Management Material